Reporting of 6-month vs 12-month data in a clinical trial of celecoxib - PubMed (original) (raw)

Comment

. 2001 Nov 21;286(19):2398-400.

• PMID: 11712925

Comment

Reporting of 6-month vs 12-month data in a clinical trial of celecoxib

J M Wright et al. JAMA. 2001.

No abstract available

PubMed Disclaimer

Comment on

• Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
  Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Silverstein FE, et al. JAMA. 2000 Sep 13;284(10):1247-55. doi: 10.1001/jama.284.10.1247. JAMA. 2000. PMID: 10979111 Clinical Trial.

Similar articles

• Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.
  Hrachovec JB, Mora M. Hrachovec JB, et al. JAMA. 2001 Nov 21;286(19):2398; author reply 2399-400. JAMA. 2001. PMID: 11712924 No abstract available.
• Arthritis. Should you be taking a COX-2 inhibitor?
  [No authors listed] [No authors listed] Harv Health Lett. 2001 Nov;27(1):1-3. Harv Health Lett. 2001. PMID: 11724695 Review. No abstract available.
• Cyclooxygenase 2 selective agents and upper gastrointestinal disease.
  Palmer RH. Palmer RH. JAMA. 2000 Apr 19;283(15):1961-2. JAMA. 2000. PMID: 10789662 No abstract available.
• Cyclooxygenase 2 selective agents and upper gastrointestinal disease.
  Fernandez H, Lesser GT. Fernandez H, et al. JAMA. 2000 Apr 19;283(15):1961; author reply 1962. JAMA. 2000. PMID: 10789661 No abstract available.
• COX-2 inhibitors: the next generation of non-steroidal anti-inflammatory drugs.
  Schachna L, Ryan PF. Schachna L, et al. Med J Aust. 1999 Aug 16;171(4):175-6. doi: 10.5694/j.1326-5377.1999.tb123592.x. Med J Aust. 1999. PMID: 10494231 Review. No abstract available.

Cited by

• Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.
  Hawkey CJ, Langman MJ. Hawkey CJ, et al. Gut. 2003 Apr;52(4):600-8. doi: 10.1136/gut.52.4.600. Gut. 2003. PMID: 12631678 Free PMC article. Review.
• Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations.
  Scolnik M, Singh G. Scolnik M, et al. Open Access Rheumatol. 2011 Aug 3;3:53-62. doi: 10.2147/OARRR.S14568. eCollection 2011. Open Access Rheumatol. 2011. PMID: 27790004 Free PMC article. Review.
• Transparency in drug regulation: mirage or oasis?
  Lexchin J, Mintzes B. Lexchin J, et al. CMAJ. 2004 Nov 23;171(11):1363-5. doi: 10.1503/cmaj.1041446. CMAJ. 2004. PMID: 15557590 Free PMC article. No abstract available.
• Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study.
  DiSantostefano RL, Sampson T, Le HV, Hinds D, Davis KJ, Bakerly ND. DiSantostefano RL, et al. PLoS One. 2014 May 30;9(5):e97149. doi: 10.1371/journal.pone.0097149. eCollection 2014. PLoS One. 2014. PMID: 24878543 Free PMC article.
• Selective COX-2 inhibitors: a health economic perspective.
  Schwappach DL, Koeck CM. Schwappach DL, et al. Wien Med Wochenschr. 2003;153(5-6):116-22. doi: 10.1046/j.1563-258x.2003.03006.x. Wien Med Wochenschr. 2003. PMID: 12705064 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Research Materials

  • NCI CPTC Antibody Characterization Program